IL157465A0 - Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders - Google Patents

Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders

Info

Publication number: IL157465A0
Authority: IL; Israel
Prior art keywords: estrogen; agonists; vitamin; treatment; combination
Prior art date: 2001-03-01

Application number

IL15746502A

Other languages

English (en)

Original Assignee

Pfizer Products Inc Pfizer Pro

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-01

Filing date

2002-02-20

Publication date

2004-03-28

2002-02-20 Application filed by Pfizer Products Inc Pfizer Pro filed Critical Pfizer Products Inc Pfizer Pro

2004-03-28 Publication of IL157465A0 publication Critical patent/IL157465A0/xx

Links

229940011871 estrogen Drugs 0.000 title 2
239000000262 estrogen Substances 0.000 title 2
239000000556 agonist Substances 0.000 title 1
208000010877 cognitive disease Diseases 0.000 title 1
229960002715 nicotine Drugs 0.000 title 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title 1
239000004031 partial agonist Substances 0.000 title 1
229940088594 vitamin Drugs 0.000 title 1
229930003231 vitamin Natural products 0.000 title 1
235000013343 vitamin Nutrition 0.000 title 1
239000011782 vitamin Substances 0.000 title 1
150000003722 vitamin derivatives Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Psychology (AREA)
Virology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

IL15746502A 2001-03-01 2002-02-20 Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders IL157465A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27256601P	2001-03-01	2001-03-01
PCT/IB2002/000515 WO2002069948A1 (en)	2001-03-01	2002-02-20	Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders

Publications (1)

Publication Number	Publication Date
IL157465A0 true IL157465A0 (en)	2004-03-28

Family

ID=23040351

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL15746502A IL157465A0 (en)	2001-03-01	2002-02-20	Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders

Country Status (33)

Country	Link
US (2)	US20020193360A1 (pl)
EP (1)	EP1363606A1 (pl)
JP (1)	JP2004527500A (pl)
KR (1)	KR20030076717A (pl)
CN (1)	CN1494422A (pl)
AP (1)	AP2002002465A0 (pl)
AR (1)	AR033425A1 (pl)
BG (1)	BG108131A (pl)
BR (1)	BR0207802A (pl)
CA (1)	CA2439581A1 (pl)
CR (1)	CR7059A (pl)
CZ (1)	CZ20032338A3 (pl)
DO (1)	DOP2002000345A (pl)
EA (1)	EA200300854A1 (pl)
EC (1)	ECSP034759A (pl)
EE (1)	EE200300422A (pl)
GT (1)	GT200200039A (pl)
HU (1)	HUP0303448A3 (pl)
IL (1)	IL157465A0 (pl)
IS (1)	IS6905A (pl)
MA (1)	MA26999A1 (pl)
MX (1)	MXPA03007834A (pl)
NO (1)	NO20033821L (pl)
NZ (1)	NZ527397A (pl)
OA (1)	OA12554A (pl)
PA (1)	PA8540701A1 (pl)
PE (1)	PE20020927A1 (pl)
PL (1)	PL364081A1 (pl)
SK (1)	SK10752003A3 (pl)
TN (1)	TNSN02018A1 (pl)
UY (1)	UY27188A1 (pl)
WO (1)	WO2002069948A1 (pl)
ZA (1)	ZA200306193B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050065205A1 (en) *	2002-03-07	2005-03-24	Daniel Alkon	Methods for Alzheimer's disease treatment and cognitive enhance
US20080004332A1 (en) *	2002-03-07	2008-01-03	Alkon Daniel L	Methods for alzheimer's disease treatment and cognitive enhancement
US6825229B2 (en)	2002-03-07	2004-11-30	Blanchette Rockefeller Neurosciences Institute	Methods for Alzheimer's Disease treatment and cognitive enhancement
WO2005000806A2 (en)	2003-06-10	2005-01-06	Georgetown University	Ligands for nicotinic acetylcholine receptors, and methods of making and using them
TW201206425A (en)	2004-05-18	2012-02-16	Brni Neurosciences Inst	Treatment of depressive disorders
US8510055B2 (en)	2005-08-03	2013-08-13	The Johns Hopkins University	Methods for characterizing and treating cognitive impairment in aging and disease
EP1924712B1 (en) *	2005-08-03	2018-10-03	The Johns Hopkins University	Methods for characterizing and treating cognitive impairment in aging and disease
ES2573733T3 (es)	2006-05-22	2016-06-09	The Board Of Trustees Of The Leland Stanford Junior University	Tratamiento farmacológico del deterioro cognitivo
AU2013202426B2 (en) *	2006-10-16	2015-08-06	Bionomics Limited	Novel anxiolytic compounds
JP5373613B2 (ja) *	2006-10-16	2013-12-18	バイオノミクスリミテッド	新規な抗不安薬化合物
US10954231B2 (en)	2006-10-16	2021-03-23	Bionomics Limited	Anxiolytic compounds
EP3332797A3 (en)	2007-02-09	2018-08-01	Blanchette Rockefeller Neurosciences Institute	Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury
EP2268639A2 (en) *	2008-05-22	2011-01-05	Teva Pharmaceutical Industries Ltd.	Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
WO2009155403A2 (en) *	2008-06-19	2009-12-23	Teva Pharmaceutical Industries Ltd.	Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) *	2008-07-10	2010-01-14	Revital Lifshitz-Liron	Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US10206921B2 (en) *	2009-06-03	2019-02-19	The Regents Of The University Of California	Methods and compositions for treating a subject for central nervous system (CNS) injury
EP2438054A1 (en) *	2009-06-22	2012-04-11	Teva Pharmaceutical Industries Ltd.	Solid states forms of varenicline salts and processes for preparation thereof
EP3034079B1 (en)	2010-11-15	2018-01-10	Agenebio, Inc.	Pyridazine derivatives, compositions and methods for treating cognitive impairment
CA2828780A1 (en)	2011-03-02	2012-09-07	Bionomics Limited	Novel small-molecules as therapeutics
US20140051701A1 (en) *	2011-03-02	2014-02-20	Bionomics Limited	Methods of treating a disease or condition of the central nervous system
EP2707367B1 (en)	2011-05-12	2019-10-09	Bionomics Limited	Methods for preparing naphthyridines
EP3083569B1 (en)	2013-12-20	2022-01-26	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP6987384B2 (ja)	2015-06-19	2021-12-22	エージンバイオ，インコーポレイテッド	ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US20180170941A1 (en)	2016-12-19	2018-06-21	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en)	2016-12-19	2022-11-22	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11414425B2 (en)	2018-06-19	2022-08-16	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN116008442B (zh) *	2023-03-27	2023-06-30	上海赛默罗生物科技有限公司	α5-GABAA受体调节剂的合成中间体的杂质检测方法
CN116077459B (zh) *	2023-04-10	2023-07-07	上海赛默罗生物科技有限公司	α5-GABAA受体调节剂的胶囊剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL338783A1 (en) *	1997-08-25	2000-11-20	Neurogen Corp	Substituted 4-oxo-naphtyridin-3-carboxamides as ligands of cerebral gaba receptors
AU5289600A (en) *	1999-05-25	2000-12-12	Neurogen Corporation	4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands

2002
- 2002-02-20 WO PCT/IB2002/000515 patent/WO2002069948A1/en not_active Ceased
- 2002-02-20 HU HU0303448A patent/HUP0303448A3/hu unknown
- 2002-02-20 EP EP02700509A patent/EP1363606A1/en not_active Withdrawn
- 2002-02-20 BR BR0207802-3A patent/BR0207802A/pt not_active IP Right Cessation
- 2002-02-20 EA EA200300854A patent/EA200300854A1/ru unknown
- 2002-02-20 MX MXPA03007834A patent/MXPA03007834A/es unknown
- 2002-02-20 OA OA1200300213A patent/OA12554A/en unknown
- 2002-02-20 JP JP2002569125A patent/JP2004527500A/ja active Pending
- 2002-02-20 KR KR10-2003-7011366A patent/KR20030076717A/ko not_active Ceased
- 2002-02-20 PL PL02364081A patent/PL364081A1/pl not_active Application Discontinuation
- 2002-02-20 SK SK1075-2003A patent/SK10752003A3/sk not_active Application Discontinuation
- 2002-02-20 NZ NZ527397A patent/NZ527397A/en unknown
- 2002-02-20 CZ CZ20032338A patent/CZ20032338A3/cs unknown
- 2002-02-20 CA CA002439581A patent/CA2439581A1/en not_active Abandoned
- 2002-02-20 EE EEP200300422A patent/EE200300422A/xx unknown
- 2002-02-20 IL IL15746502A patent/IL157465A0/xx unknown
- 2002-02-20 CN CNA028058046A patent/CN1494422A/zh active Pending
- 2002-02-26 PE PE2002000157A patent/PE20020927A1/es not_active Application Discontinuation
- 2002-02-26 US US10/083,743 patent/US20020193360A1/en not_active Abandoned
- 2002-02-26 DO DO2002000345A patent/DOP2002000345A/es unknown
- 2002-02-27 GT GT200200039A patent/GT200200039A/es unknown
- 2002-02-27 UY UY27188A patent/UY27188A1/es not_active Application Discontinuation
- 2002-02-27 AR ARP020100693A patent/AR033425A1/es not_active Application Discontinuation
- 2002-02-28 AP APAP/P/2002/002465A patent/AP2002002465A0/en unknown
- 2002-02-28 TN TNTNSN02018A patent/TNSN02018A1/fr unknown
- 2002-02-28 PA PA20028540701A patent/PA8540701A1/es unknown
2003
- 2003-08-07 IS IS6905A patent/IS6905A/is unknown
- 2003-08-11 ZA ZA200306193A patent/ZA200306193B/en unknown
- 2003-08-19 MA MA27286A patent/MA26999A1/fr unknown
- 2003-08-25 BG BG108131A patent/BG108131A/xx unknown
- 2003-08-25 CR CR7059A patent/CR7059A/es not_active Application Discontinuation
- 2003-08-28 NO NO20033821A patent/NO20033821L/no not_active Application Discontinuation
- 2003-09-01 EC EC2003004759A patent/ECSP034759A/es unknown
- 2003-12-02 US US10/727,934 patent/US20040082555A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EE200300422A (et)	2004-02-16
US20020193360A1 (en)	2002-12-19
WO2002069948A1 (en)	2002-09-12
AR033425A1 (es)	2003-12-17
HUP0303448A2 (hu)	2004-01-28
EP1363606A1 (en)	2003-11-26
KR20030076717A (ko)	2003-09-26
OA12554A (en)	2006-06-07
SK10752003A3 (sk)	2004-08-03
PL364081A1 (pl)	2004-12-13
ZA200306193B (en)	2004-08-11
NO20033821D0 (no)	2003-08-28
ECSP034759A (es)	2003-10-28
CR7059A (es)	2004-03-10
IS6905A (is)	2003-08-07
CN1494422A (zh)	2004-05-05
MA26999A1 (fr)	2004-12-20
DOP2002000345A (es)	2002-12-15
UY27188A1 (es)	2002-10-31
PE20020927A1 (es)	2002-10-30
EA200300854A1 (ru)	2004-02-26
AP2002002465A0 (en)	2002-06-30
CA2439581A1 (en)	2002-09-12
MXPA03007834A (es)	2003-12-08
NO20033821L (no)	2003-09-10
NZ527397A (en)	2005-05-27
TNSN02018A1 (fr)	2005-12-23
HUP0303448A3 (en)	2005-05-30
JP2004527500A (ja)	2004-09-09
GT200200039A (es)	2002-11-21
CZ20032338A3 (cs)	2004-08-18
PA8540701A1 (es)	2002-09-30
US20040082555A1 (en)	2004-04-29
BG108131A (en)	2004-09-30
BR0207802A (pt)	2004-03-09

Publication	Publication Date	Title
HUP0303448A3 (en)	2005-05-30	Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders
IL158745A0 (en)	2004-05-12	Heating member for combination heating and chilling apparatus, and methods
PL373626A1 (pl)	2005-09-05	Leczenie zaburzeń centralnego układu nerwowego
NZ525103A (en)	2004-12-24	Combination use of acetylcholinesterase inhibitors and GABAA inverse agonists for the treatment of cognitive disorders
GB2371557B (en)	2004-02-18	Method for the preparation of hydrogenated hydrocarbons
AU8821301A (en)	2002-01-08	Selective androgen receptor modulators and methods for their identification, design and use
PL362030A1 (pl)	2004-10-18	Selektywni agoniści receptora EP4 do leczenia osteoporozy
IL157163A0 (en)	2004-02-08	Composition, apparatus and method for skin rejuvenation
AU2003282679A8 (en)	2004-05-04	Hydroxypyrazoles for use against metabolic-related disorders
MXPA02008801A (es)	2003-07-07	Derivados de indol, proceso para la preparacion de los mismos y su uso.
PT1444215E (pt)	2006-10-31	Derivados de 1,2,4-triadiazolio como moduladores do receptor de melanocortina
NO20030213D0 (no)	2003-01-16	Anvendelse av D2/D3 reseptor-agonister for behandling av fibromyalgi
ZA200108797B (en)	2003-04-25	Process for the preparation of non-steroidal glucocorticoid receptor modulators.
IL158115A0 (en)	2004-03-28	Sapogenin derivatives, their synthesis and use, and methods based upon their use
MXPA03004677A (es)	2003-09-05	Derivados de piperazina, su preparacion y su uso para tratamiento de trastornos del sistema nervioso central (snc).
PL368556A1 (pl)	2005-04-04	Sposoby leczenia albo zapobiegania chorobom skóryprzy zastosowaniu czynników wiążących CD2
IL159570A0 (en)	2004-06-01	Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
DE60039652D1 (de)	2008-09-11	Heizwiderstände, Heizwiderstände, die für keramischen Heizelementen bestimmt sind, und keramische Heizelemente, die diegleichen benützen
ZA200400313B (en)	2004-11-01	Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine.
MXPA03006478A (es)	2003-09-22	Derivados de cromano, procedimiento para su preparacion y su uso como agentes antitumorales.
AU2003263301A8 (en)	2004-03-29	Alternative processes for the preparation of d- (+) -morphine, and d- (+) - morphine tartrate
PL370842A1 (pl)	2005-05-30	Selektywni agoniści receptora dopaminowego D3 do leczenia dysfunkcji seksualnej
MXPA03006249A (es)	2003-09-22	Derivados de 2-arilimino-2,3-dihidrotiazoles, sus procesos de preparacion y su uso terapeutico.
MXPA03004190A (es)	2003-09-22	Tratamiento de trastornos de ansiedad.
PL376756A1 (pl)	2006-01-09	Zastosowanie S-10-hydroksy-10,11-dihydro-karbamazepiny do leczenia zaburzeń lękowych i chorób dwubiegunowych